

Supplementary Material

Supplementary Table 1. Baseline patient characteristics, in-hospital treatment and mortality by hospital level according to coronary revascularization rate (in deciles)

	Hospitals in Decile 1	Hospitals in Decile 2	Hospitals in Decile 3	Hospitals in Decile 4	Hospitals in Decile 5	Hospitals in Decile 6	Hospitals in Decile 7	Hospitals in Decile 8	Hospitals in Decile 9	Hospitals in Decile 10
Number of hospitals	106	31	70	91	49	59	76	59	67	135
Number of patients	845	575	906	1,536	1,289	1,020	1,590	1,335	1,357	1,477
(% of patients)	(7.1)	(4.8)	(7.6)	(12.9)	(10.8)	(8.6)	(13.3)	(11.2)	(11.4)	(12.4)
Baseline characteristics										
Age (years), mean (SD)	62.9 (12.0)	62.3 (12.2)	64.2 (12.6)	62.9 (11.7)	62.7 (11.3)	62.9 (11.9)	63.3 (11.6)	61.8 (11.2)	62.3 (11.1)	62.4 (11.5)
Male, n (%)	563 (66.6)	397 (69.0)	570 (62.9)	999 (65.0)	907 (70.4)	726 (71.2)	1,121 (70.5)	975 (73.0)	1,021 (75.2)	1,128 (76.4)
Hypertension, n (%)	585 (70.1)	364 (63.6)	609 (67.3)	1,002 (65.7)	798 (62.6)	631 (62.4)	1,042 (66.0)	807 (61.0)	818 (61.3)	874 (59.5)
Hypercholesterolemia, n (%)	324 (41.5)	226 (40.1)	321 (36.6)	540 (36.7)	396 (33.1)	348 (34.9)	654 (42.5)	491 (37.7)	481 (37.1)	461 (32.0)
Diabetes mellitus, n (%)	289 (34.7)	186 (32.6)	261 (28.9)	463 (30.7)	309 (24.3)	269 (26.7)	437 (27.8)	333 (25.2)	324 (24.3)	363 (24.8)
Currently smoking, n (%)	350 (45.2)	202 (39.2)	395 (46.4)	731 (51.3)	546 (45.7)	362 (39.1)	620 (41.0)	526 (41.4)	450 (35.1)	564 (40.2)
Prior CVD, n (%)	373 (47.1)	251 (43.8)	442 (49.3)	655 (43.4)	545 (44.0)	415 (41.5)	709 (45.1)	556 (41.8)	579 (43.2)	514 (35.0)

Clinical status on admission, n (%)

LVEF <40%	64 (8.7)	91 (16.5)	65 (7.9)	96 (6.7)	59 (5.1)	66 (7.2)	116 (8.0)	79 (6.4)	81 (6.5)	80 (5.6)
Creatinine ≥1.2 mg/dl	269 (35.5)	153 (27.9)	206 (24.0)	362 (24.4)	305 (24.5)	228 (23.2)	369 (23.8)	274 (21.8)	314 (24.0)	335 (23.4)
Glucose >160 g/dl	211 (28.4)	128 (26.5)	158 (19.4)	263 (20.3)	232 (20.5)	183 (20.6)	252 (18.0)	228 (18.9)	225 (18.8)	255 (18.6)
Hemoglobin ≤13 mg/dl	263 (35.4)	204 (37.3)	282 (33.4)	520 (35.0)	381 (30.7)	301 (31.0)	499 (33.4)	376 (29.5)	388 (31.1)	388 (26.8)

Patient management, n (%)

Coronary revascularization	0 (0.0)	67 (11.9)	258 (28.7)	680 (45.0)	724 (56.8)	658 (64.8)	1,137 (71.6)	1,051 (78.8)	1,173 (86.7)	1,428 (96.8)
PCI	0 (0.0)	55 (9.8)	244 (27.1)	649 (42.9)	694 (54.3)	627 (61.7)	1,069 (67.4)	1,006 (75.4)	1,154 (85.3)	1,411 (95.6)
CABG	0 (0.0)	12 (2.1)	16 (1.8)	31 (2.0)	34 (2.7)	31 (3.1)	74 (4.7)	49 (3.7)	20 (1.5)	18 (1.2)
DAPT at discharge	650 (76.9)	402 (69.9)	621 (68.5)	1,242 (80.9)	1,025 (79.5)	829 (81.3)	1,359 (85.5)	1,159 (86.8)	1,234 (90.9)	1,393 (94.3)
Statin at discharge	712 (85.2)	519 (90.7)	813 (89.7)	1,367 (90.4)	1,150 (89.8)	873 (86.3)	1,463 (92.4)	1,228 (92.2)	1,276 (94.3)	1,382 (93.8)
BB at discharge	632 (75.5)	481 (83.9)	678 (74.9)	1,120 (73.7)	958 (74.5)	770 (75.6)	1,168 (73.7)	1,076 (80.8)	1,119 (82.6)	1,143 (77.4)
ACEI/ARB at discharge	601 (71.7)	411 (71.7)	584 (64.5)	971 (63.9)	794 (61.9)	702 (69.0)	1,091 (68.9)	898 (67.4)	938 (69.2)	964 (65.3)
MRA at discharge	67 (8.0)	39 (7.0)	60 (6.7)	97 (6.4)	78 (6.1)	43 (4.2)	99 (6.3)	75 (5.6)	66 (4.9)	109 (7.4)
2-year mortality	78 (9.2)	66 (11.5)	70 (7.7)	111 (7.2)	79 (6.1)	49 (4.8)	84 (5.3)	61 (4.6)	45 (3.3)	53 (3.6)

Red depicts the highest and blue the lowest value for each row.

ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BB, beta-blocker; CABG, coronary artery bypass grafting; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; PCI, percutaneous coronary intervention; SD, standard deviation.

Supplementary Table 2. Baseline patient characteristics, in-hospital treatment and mortality by region

	Southern Europe	Northern Europe	Eastern Europe	Latin America	China	SK, HK & Singapore	India	South East Asia
N, (%)	1,213 (10.2)	2,173 (18.2)	1,235 (10.4)	1,003 (8.4)	4,253 (35.7)	553 (4.6)	986 (8.3)	514 (4.3)
Baseline characteristics								
Age (years), mean (SD)	65.9 (12.5)	64.6 (12.3)	61.0 (10.9)	63.2 (11.6)	61.9 (10.8)	63.7 (11.8)	59.0 (11.4)	63.8 (12.3)
Male, n (%)	903 (74.4)	1,559 (71.7)	868 (70.3)	666 (66.4)	2,904 (68.3)	387 (70.0)	780 (79.1)	340 (66.2)
Hypertension, n (%)	797 (66.6)	1,294 (60.4)	859 (70.2)	759 (76.5)	2,667 (63.1)	318 (57.5)	485 (49.5)	351 (68.3)
Hypercholesterolemia, n (%)	720 (60.9)	1,150 (54.6)	586 (49.5)	497 (53.6)	855 (21.1)	143 (26.1)	52 (5.5)	239 (47.0)
Diabetes mellitus, n (%)	408 (34.1)	460 (21.4)	307 (25.2)	336 (34.1)	1,046 (25.0)	169 (30.6)	348 (35.5)	160 (31.1)
Currently smoking, n (%)	384 (34.7)	649 (32.0)	475 (40.8)	350 (37.8)	1,901 (46.5)	243 (46.7)	508 (62.0)	236 (47.1)
Prior CVD, n (%)	553 (46.0)	979 (45.2)	642 (52.3)	498 (50.7)	1,805 (43.2)	171 (31.2)	192 (21.2)	199 (38.7)
Clinical status on admission, n (%)								
LVEF <40	797 (6.7)	148 (6.8)	128 (10.4)	88 (8.8)	132 (3.1)	38(6.9)	106 (10.8)	66 (12.8)

Creatinine \geq1.2 mg/dl	249 (22.5)	604 (28.8)	238 (19.7)	236 (26.1)	911 (21.7)	141 (26.1)	219 (25.6)	217 (42.7)
Glucose >160 g/dl	239 (22.4)	331 (18.0)	240 (21.3)	216 (25.6)	664 (16.1)	134 (28.2)	212 (34.3)	99 (22.5)
Hemoglobin \leq13 mg/dl	318 (28.6)	482 (23.2)	266 (21.9)	264 (31.6)	1428 (34.0)	181 (33.3)	393 (49.4)	270 (53.2)

Patient management, n (%)

Coronary revascularization	830 (68.7)	1,420 (65.4)	649 (53.3)	386 (38.8)	2,792 (66.1)	437 (79.3)	464 (51.8)	198 (38.6)
PCI	808 (66.8)	1,302 (60.0)	625 (51.0)	349 (35.1)	2,768 (65.6)	433 (78.6)	440 (49.3)	184 (35.8)
CABG	24 (2.0)	123 (5.7)	24 (2.0)	38 (3.8)	34 (0.8)	4 (0.7)	24 (2.6)	14 (2.7)
DAPT at discharge	1,017 (83.8)	1,717 (79.0)	979 (79.3)	789 (78.7)	3700 (87.0)	487 (88.1)	764 (77.5)	461 (89.7)
Statin at discharge	1,117 (92.1)	1,998 (92.0)	1,113 (90.3)	899 (91.5)	3,951 (93.3)	442 (80.4)	794 (81.9)	469 (91.3)
BB at discharge	985 (81.2)	1,860 (85.6)	1,127 (91.3)	801 (79.9)	3,033 (71.3)	420 (76.0)	572 (58.0)	347 (67.5)
ACEI/ARB at discharge	916 (75.5)	1,500 (69.0)	1,021 (82.7)	734 (73.2)	2,636 (62.0)	356 (64.4)	445 (45.1)	346 (67.3)
MRA at discharge	66 (5.4)	97 (4.5)	119 (9.6)	88 (8.8)	256 (6.0)	28 (5.1)	61 (6.2)	18 (3.5)

2-year mortality	81 (6.7)	100 (4.6)	94 (7.6)	97 (9.7)	169 (4.0)	21 (3.8)	62 (6.3)	60 (11.7)
-------------------------	----------	-----------	----------	----------	-----------	----------	----------	-----------

Supplementary Table 2 is reproduced with minor changes from Tables 1 & 2 from reference 8: Bueno H et al. *Clin Res Cardiol.* 2018 Sep;107(9):836-844, with permission from Springer.

Red depicts the highest and blue the lowest value for each row.

ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BB, beta-blocker; CABG, coronary artery bypass grafting; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; HK, Hong Kong; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; PCI, percutaneous coronary intervention; SD, standard deviation; SK, South Korea.

Supplementary Table 3. Coronary revascularization rate (CRR) and 2-year post-discharge mortality rate (2YMR) by country

Country	No. of patients	CRR (%)	2YMR (%)
Greece	151	27.8	11.3
The Netherlands	293	60.1	5.5
Belgium	274	68.6	3.3
France	175	63.4	6.3
Spain	442	71.3	7.2
Italy	445	81.3	4.7
Romania	332	12.3	9.0
United Kingdom	451	50.8	6.2
Denmark	159	58.5	3.8
Norway	442	73.3	2.5
Poland	317	76.3	8.8
Germany	333	80.5	4.5
Mexico	277	44.8	11.2
Argentina	260	51.5	5.8
Brazil	192	42.2	6.8
Venezuela	274	17.2	13.9
Turkey	520	58.7	6.7
China	4,253	65.6	4.0
Hong Kong	69	42.0	13.0
Luxembourg	1	100.0	0.0
India	986	47.1	6.3
Finland	220	64.1	6.8
Slovenia	66	92.4	1.5
South Korea	429	86.5	2.6
Malaysia	67	19.4	19.4

Singapore	55	67.3	1.8
Vietnam	80	53.8	5.0
Thailand	367	38.7	11.7

Acknowledgments

Supplementary Table 2: Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer Nature, Clinical Research in Cardiology, Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome, Bueno H, Rossello X, Pocock S, et al., © 2018.